Olmesartan Medoxomil Is Associated with Decreased Plasma AGEs, Pentosidine, and N-(Epsilon)-Carboxymethyl-Lysine Levels in Hemodialysis Patients

Background. Advanced glycation end products (AGEs) are associated with comorbidity and death among patients on hemodialysis (HD). Angiotensin II type 1 receptor blockers (ARBs) can decrease the formation of AGEs in vitro. This study examines the ability of various ARBs to decrease plasma AGE levels in hypertensive patients on HD. Methods. This preliminary randomized prospective study included 24 hypertensive patients on HD who were treated with candesartan (8 mg/day). The patients were randomly assigned to an olmesartan (20 mg/day, n = 12) or a telmisartan (40 mg/day, n = 12) group and followed up 24 weeks. Blood pressure was monitored before each HD session, and plasma pentosidine, N-(epsilon)-carboxymethyl-lysine (CML), serum malondialdehyde-low-density lipoprotein (LDL), high-sensitive CRP, and serum total free radical (TFR) were measured at baseline, and at 4, 12, and 24 weeks. Results. Olmesartan was significantly associated with decreased systolic blood pressure compared with telmisartan. After 24 weeks of treatment, plasma pentosidine and CML levels were significantly decreased and serum TFR levels tended to be decreased in the olmesartan group, but remained unchanged in the telmisartan group. Conclusions. These results suggest that olmesartan can help to decrease plasma AGE levels in patients on HD.

[1]  T. Akizawa,et al.  Olmesartan Medoxomil Treatment Is Associated with Decreased Plasma B-Type Natriuretic Peptide Levels in Patients on Hemodialysis , 2012, Clinical and experimental hypertension.

[2]  T. Akizawa,et al.  Assessment of Inflow of Endotoxin and Its Fragments in Patients on Maintenance Hemodialysis , 2011, Blood Purification.

[3]  R. Morishita,et al.  Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. , 2011, Biochemical and biophysical research communications.

[4]  T. Akizawa,et al.  Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[5]  R. Guo,et al.  Association of serum pentosidine with arterial stiffness in hemodialysis patients. , 2010, Artificial organs.

[6]  S. Kennedy,et al.  RAGE, vascular tone and vascular disease. , 2009, Pharmacology & therapeutics.

[7]  Chie Aoki,et al.  Telmisartan inhibits cytokine-induced nuclear factor-κB activation independently of the peroxisome proliferator-activated receptor-γ , 2009, Hypertension Research.

[8]  A. Smit,et al.  AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis , 2009, Autoimmunity.

[9]  Y. Toya,et al.  Urinary Oxidative Stress Markers Closely Reflect the Efficacy of Candesartan Treatment for Diabetic Nephropathy , 2008, Nephron Experimental Nephrology.

[10]  K. Miyatake,et al.  Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome , 2008, Hypertension Research.

[11]  G. Wolf,et al.  Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension , 2008, Nephron Clinical Practice.

[12]  P. Ernsberger,et al.  Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect? , 2007 .

[13]  S. Aslam,et al.  Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. , 2006, Kidney international.

[14]  P. Stenvinkel,et al.  Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. , 2006, Clinical nephrology.

[15]  T Niwa,et al.  Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. , 2006, Kidney international.

[16]  J. Nagy,et al.  Serum carboxymethyllysine predicts mortality in hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  K. Tomita,et al.  Effect of Telmisartan on Ambulatory Blood Pressure Monitoring, Plasma Brain Natriuretic Peptide, and Oxidative Status of Serum Albumin in Hemodialysis Patients , 2005, Hypertension Research.

[18]  Reindert Graaff,et al.  Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  M. Nangaku,et al.  Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  M. Pugsley,et al.  A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker , 2005, Journal of cardiovascular pharmacology.

[21]  D. Tsikas,et al.  Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  U. Ott,et al.  Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.

[23]  E. Lonn,et al.  Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  S. Aslam,et al.  Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[25]  P. Stenvinkel,et al.  Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. , 2003, Journal of the American Society of Nephrology : JASN.

[26]  M. Nangaku,et al.  Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[28]  D. Choudhury,et al.  Advanced glycation end products: a Nephrologist's perspective. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  C. Fraga,et al.  Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[31]  F. Locatelli,et al.  What We Know About Oxidative Stress in Patients with Chronic Kidney Disease on Dialysis—Clinical Effects, Potential Treatment, and Prevention , 2011, Seminars in dialysis.

[32]  T. Akizawa,et al.  Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[33]  P. Ernsberger,et al.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? , 2007, Current opinion in pharmacology.

[34]  Hirokazu Honda,et al.  Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  L. Bolognini,et al.  The radical cation of N,N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples , 2000 .

[36]  J. Baynes,et al.  New biomarkers of Maillard reaction damage to proteins. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.